Monjuvi (tafasitamab) targets the CD-19, a protein on the surface of B-cells that is also targeted by Amgen’s bispecific antibody Blincyto (blinatumomab) for acute lymphoblastic leukaemia (ALL ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Minjuvi/Monjuvi net product revenue increased 265% to $32.81 million, as the company recognized all revenue from sales of Monjuvi in the United States following the acquisition of exclusive global ...

A potential approval is expected in the second half of 2025. The uptake of Pemazyre and other newly approved drugs like Monjuvi and Tabrecta is also impressive. A supplemental biologics license ...

ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least ...